Companies: 10,795·Total market cap: $144.5T
Cerevel Therapeutics Holdings, Inc.

Cerevel Therapeutics Holdings, Inc.

CERENASDAQHealthcare
$44.96
+$0.33(+0.74%)
Market Cap$8.2B
P/E Ratio
52W High$44.99
52W Low$19.59
Overview

Cerevel Therapeutics Holdings, Inc. (CERE) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · CERE · as of Jun 9, 2026

Key Statistics

EPS (TTM)$-2.73cere eps ttm · cere earnings per shareEarnings history
PE Ratio (TTM)cere pe ratio ttm · cere price to earningsPE Ratio deep dive
Revenue (TTM)$8.2Mcere revenue ttm · cere annual revenueFull revenue history
Dividend YieldNo Dividenddoes cere pay dividends · cere dividend yieldDividend history
Shares Outstanding162.1Mcere shares outstanding · cere floatShares outstanding history
Next EarningsTBAcere earnings date · cere next earningsEarnings history

Financial Snapshot

Full Financials
FY 2023Revenue$0.00
202120222023
cerevel therapeutics holdings, inc. revenue · cere revenue 2023
FY 2023Net Income-$432.8M▼ 23.14% YoY
202120222023
cerevel therapeutics holdings, inc. net income · cere profit 2023
FY 2023EPS$-2.67▼ 15.09% YoY
202120222023
cere eps · cerevel therapeutics holdings, inc. earnings per share 2023
TTM:Revenue: $8.2MNet Income: -$460.5MEPS: $-2.73View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Hold16 analystsis cere a buy · cere analyst rating
Strong Buy
0
Buy
6
Hold
10
Sell
0
Strong Sell
0
12-Month Price Target
$27.00Low
$44.96Current
$33.50Avg Target25.49% downside
$40.00High
cere price target · cere 12 month forecast

Total: 16 · Buy rate: 37.5%

The CERE analyst consensus is Hold, based on ratings from 16 Wall Street analysts over the past 3 months. The average 12-month price target is $33.50, representing -25.49% downside from the current price of $44.96.

Stock Performance

Full History
1D+0.00%
1W+0.00%
1M+0.74%
3M+10.63%
YTD+6.52%
1Y+87.88%
5Y+277.82%

About Cerevel Therapeutics Holdings, Inc.

CEORonald C. Renaud Jr.,
IPO DateJul 30, 2020
Employees355
CountryUS

Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing treatments for a range of neuroscience disorders. The company boasts a robust pipeline of therape…

what is cerevel therapeutics holdings, inc. · cere stock overview · cerevel therapeutics holdings, inc. company profile · who is cerevel therapeutics holdings, inc. ceo · cere NASDAQ · cerevel therapeutics holdings, inc. headquarters · cerevel therapeutics holdings, inc. business segments

About Stock Overview & Key Data

Cerevel Therapeutics Holdings, Inc. (CERE) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jul 30, 2020. As of the latest trading session, CERE stock price is $44.96, with a market capitalization of $8.2B. The stock has returned +87.88% over the past 12 months and +6.52% year-to-date.

According to 16 Wall Street analysts, the consensus rating for Cerevel Therapeutics Holdings, Inc. stock is Hold, with an average 12-month price target of $33.50. In fiscal year 2023, Cerevel Therapeutics Holdings, Inc. reported revenue of — and net income of -$432.8M. For detailed data — including Cerevel Therapeutics Holdings, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Cerevel Therapeutics Holdings, Inc. (CERE) stock price is $44.96. The stock is traded on NASDAQ under the ticker symbol CERE. The 52-week range is $19.59 – $44.99.

CERE stock priceCERE quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 9, 2026Not investment advice